Bal Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bal Pharma Ltd. on BSE

Load latest

Bal Pharma Ltd.

30 Jun 2023

84.34

0.17%

Corp. Note

BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / …

BSE India

We are submitting to the exchange intimation received from our R&T agents i.e TSR Consultants Pvt Ltd , Mumbai regarding issue of duplicate share certificate in lieu of lost/misplaced original share certificate to one of our shareholder. Please take the intimation on record.

pdf

Bal Pharma Ltd.

28 Jun 2023

84.34

0.17%

SAST

BAL PHARMA LTD. - 524824 - Closure of Trading Window

BSE India

Pursuant to the Code of Conduct of the Company and as per the amended provisions of SEBI(Prohibition of Insider Trading ) Regulations, We wish to inform the exchanges that the trading window for dealing with the securities of the Company on designated employees and their relatives will be closed from 1st July 2023 and up to 48 hours of the declaration of the Un-Audited financial results of the Company for the quarter ended 30.06.2023. The date of the Board meeting for declaration of the Un-Audited financial results will be intimated to the exchanges in due course.

pdf

Bal Pharma Ltd.

01 Jun 2023

84.34

0.17%

Company Update

BAL PHARMA LTD. - 524824 - Announcement As Per Regulation 30 Of SEBI(LODR) Regulations Appointment Of …

BSE India

We would like to inform the exchanges that the Board of Directors of the Company vide a resolution passed by circulation has appointed Ms. Nicola Neeladri (DIN 01997936) as Additional Director of the Company to hold office from 23.05.2023 until the conclusion of ensuing General Meeting of the Company.

pdf

Bal Pharma Ltd.

31 May 2023

84.34

0.17%

Company Update

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

We are submitting to the exchange newspaper advertisements of abridged Audited standalone and Consolidated financial results of the Company for the quarter & F.Y ended 31.03.2023 announced by the Company on 29.05.2023 and published in Financial Express (English) and Sanjay vani (Kannada), on 30.05.2023.

pdf

Bal Pharma Ltd.

30 May 2023

84.34

0.17%

Annual Report

Annual report for Bal Pharma Ltd. for FY-2023

None

pdf

Bal Pharma Ltd.

29 May 2023

84.34

0.17%

Result

BAL PHARMA LTD. - 524824 - Audited Financial Results - Stand Alone And Consolidated For The …

BSE India

The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended 31.03.2023. A copy of the Audited financial statements (Standalone and Consolidated) along with auditors reports with unmodified opinion are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each i.e 10%, subject to the approval of members at the ensuing Annual General Meeting of the Company. 3.Appointed Mr.M.R Krishna Murthy (Membership No. 7568) as Cost Auditor , Mr.Parameshwar Bhat (Membership No.8860) as Secretarial Auditors and Messrs. Murugesh & Co ( Membership No.002233S) as internal auditors of the Company for the financial year 2023-2024. The meeting commenced at 4.45 P.M and concluded at 6.20 P.M on 29.05.2023.

pdf

Bal Pharma Ltd.

29 May 2023

84.34

0.17%

Company Update

BAL PHARMA LTD. - 524824 - Related Party Transactions For The Half Year Ended 31.03.2023

BSE India

We are submitting to the exchanges statement of the related party transactions for the half year ended 31.03.2023, duly reviewed by our statutory auditors.

pdf

Bal Pharma Ltd.

29 May 2023

84.34

0.17%

Board Meeting

BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Out Come Of The Board Meeting

BSE India

pdf

Bal Pharma Ltd.

26 May 2023

84.34

0.17%

Company Update

BAL PHARMA LTD. - 524824 - Announcement Under Regulation 30 Of LODR Regulations- Up Dation Of …

BSE India

We wish to inform the exchanges that the enclosed letter along with relevant annexures are sent to identified physical shareholders of the Company through our RTA , requesting them to update their PAN, KYC details and Nomination in the Company Records for smooth processing of the investors service requests. The aforesaid intimation shall be placed on the Company's website at www.balpharma.com.

pdf